BIO submitted comments to DoD, GSA, and NASA on the Proposed Rule to amend and restructure regulations on environmental and sustainability procurement (FAR Case 2022-006, Docket No. 2022-0006, Sequence No. 1 RIN 9000-AO43)
Letters, Testimony & Comments | July 25, 2023 | Medicaid
BIO submitted comments to CMS per their Notice of Proposed Rulemaking: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
Comments on Revised HSR Premerger Notification and Report Form 16 CFR Parts 801-803—Hart-Scott-Rodino Coverage, Exemption, and Transmittal Rules, Project No. P239300
Letters, Testimony & Comments | September 28, 2023 | Regulatory
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
BIO joined with other groups in writing House and Senate Agriculture Committee leaders in support of agricultural research (FFAR) funding in the farm bill.
Letters, Testimony & Comments | July 31, 2023 | Policy & Regulatory, Europe Issues
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.
In response to a Request for Information (RFI) from the Senate 340B Bipartisan Working Group, BIO submitted detailed comments on the current status of the program and suggestions for improvements.